Magnetic Resonance Imaging in Patients With Breast Cancer
NCT ID: NCT00610181
Last Updated: 2015-07-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
96 participants
OBSERVATIONAL
2008-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Magnetic Resonance Imaging in Women Recently Diagnosed With Unilateral Breast Cancer
NCT00058058
Feasibility of Short Breast MRI (SBMRI) for Screening Patients at High Risk for Breast Cancer
NCT02590458
Magnetic Resonance Imaging of Breast Cancer
NCT01035112
Magnetic Resonance Imaging in Women Receiving Chemotherapy for Stage III Breast Cancer
NCT00043017
Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer
NCT05042687
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
MRI of the breast is a technology that is better than mammograms and ultrasounds at locating cancer. Although MRI may locate more areas of cancer, it can sometimes falsely identify normal areas of the breast as cancerous.
Unlike ductal cancer of the breast (the most common type of breast cancer), lobular cancer is more difficult to see on mammograms and ultrasounds. Therefore, patients with lobular cancer of the breast may be best suited for MRI of the breast in order to more accurately determine the extent of the cancer. In addition, in young women, because the breast tissue is very dense, all types of breast tumors are harder to detect with mammogram and ultrasound and may be better seen with MRI.
A correct measurement of the size and extent of the cancer is important because this affects the recommendation for the type of surgery a patient may have.
Study Procedures:
If you agree to take part in this study, you will have an MRI of both breasts.
For the MRI, part or all of the body will be passed into a long, narrow tube scanner, which is open at both ends.
The MRI images will be compared with the images from your standard of care mammogram and ultrasound images. If the MRI shows abnormalities not seen on the mammogram or ultrasound and your doctor thinks it is necessary, you may have additional testing and/or a tumor biopsy. This is part of your standard of care.
The results of this additional MRI testing will be used by your surgeon to guide his/her recommendations for your surgery.
Information like your age, diagnosis, and results of your testing will be collected as part of the data analysis for this study.
No identifying information will be sent outside of MD Anderson. Your information will be stored on a password-protected computer. Information may be kept for up to 5 years after the study ends.
This is an investigational study. The investigational part of this study is the comparison of the outcome of MRI images to mammogram and ultrasound images in determining appropriate surgical therapy.
Up to 170 patients will be take part in this study. All will be enrolled at MD Anderson.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Breast MRI
Magnetic resonance imaging (MRI) of breast for patients with invasive lobular carcinoma of the breast.
MRI
MRI of both breasts, results used for surgery, then MRI repeated in 1 year as part of routine follow-up after surgery.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MRI
MRI of both breasts, results used for surgery, then MRI repeated in 1 year as part of routine follow-up after surgery.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. For women with invasive lobular carcinoma, if the pathology report from the diagnostic biopsy states that they have "predominantly" lobular histology or lobular cancer with "focal" areas/nests of ductal carcinoma, these cases will automatically be assumed to have at least 75% lobular component.
4. Must be able to complete the MR examination within 30 days of mammography and ultrasound of the breast.
5. Age \>18 years
6. Surgery planned at MDACC
7. Eastern Cooperative Oncology Group (ECOG) status 0-2
8. Creatinine and glomerular filtration rate measured or calculated within 2 weeks of MRI date
Exclusion Criteria
2. Patients with pacemakers
3. Patients with severe claustrophobia
4. Obese patients exceeding the equipment weight limits and/or the circumference of the MRI portal
5. Interval between MRI and conventional locoregional staging studies (mammography/breast US) greater than 30 days.
6. Known allergy to gadolinium
7. Patients with clips/prostheses/implanted devices that are not MRI compatible
8. Compromised renal function, with a measured or calculated glomerular filtration rate of less than 60 ml/min/1.73m\^2.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
M.D. Anderson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Isabelle Bedrosian, MD
Role: PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
The University of Texas M.D.Anderson Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2007-0736
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.